Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 15, 2026

Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

View original at globenewswire.com
“Total Revenue: $35 thousand in Q1 2026, compared to $110 thousand in Q1 2025.”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The $260 million GPU cluster will go live in Q3 2026, translating to approximately $21 million per quarter in revenue.

    60% confidence
  • Global AI spending is forecast to reach $2.52 trillion in 2026, a 44% increase year-over-year.

    60% confidence
  • Axe Compute's pipeline now exceeds $4 billion and the goal of closing $1 billion in new customer agreements by end of 2026 seems to be very much within reach.

    60% confidence
  • Approximately $6.7 trillion is projected to be spent on data centers globally between 2025 and 2030, of which approximately 65.7% is GPU-related.

    60% confidence
  • The Company's combined liquidity position of approximately $36.5 million is sufficient to fund operations through fiscal 2026 and beyond.

    60% confidence
  • The $4.3 million non-cash mark-to-market loss on ATH digital asset holdings in Q1 2026 was tied directly to the decline in the market price of the Aethir token during Q1.

    60% confidence
  • Q1 2026 marked the beginning of contracts for the compute business, and the April $260 million contract is the clearest signal yet of what the platform can deliver.

    60% confidence
  • As of early 2026, average GPU procurement lead times stand at 36 to 52 weeks, creating a durable commercial opportunity for Axe Compute's distributed, enterprise-first GPU compute model.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com